ClinicalTrials.gg
CompletedNCT01493687Updated Feb 18, 2021Results posted

Phase 3 Papulopustular Rosacea Study

A Phase 3 interventional study of CD5024 and Azelaic acid 15% Gel in Papulopustular Rosacea (PPR), sponsored by Galderma R&D. Completed at 50 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
683
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ivermectin in Rosacea — none open to participants now, none under way, none of them phase 3. Ivermectin · Rosacea.

Enrollment
4th of 11
683 · median 486
Started
2011
with 1 other
Phase 3
6 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
4 of 11
Galderma R&D

Among the 11 studies testing ivermectin in Rosacea, this one is the 4th largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 3, and was the 1st registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing ivermectin in Rosacea is open now. The open studies under Rosacea, anywhere →

About ivermectin

Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ivermectin in Rosacea as a file.
02

Study summary

The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.

03

Conditions studied

  • Papulopustular Rosacea (PPR)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject has papulopustular rosacea with an Investigator Global Assessment (IGA) score rated 3 (moderate) or 4 (severe),
  2. The subject has at least 15 but not more than 70 inflammatory lesions (papules and pustules) on the face.

Exclusion criteria

Exclusion Criteria:

  1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial keratosis pilaris, seborrheic dermatitis, and acne,
  2. The subject has rosacea with more than two nodules on the face.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
683 participants (actual)

Study arms

  • Experimental
    CD5024

    CD5024 1% Cream

    Drug: CD5024

  • Placebo comparator
    CD5024 Vehicle

    CD5024 Vehicle Cream

    Drug: Azelaic acid 15% Gel

Interventions

  • DrugCD5024

    CD5024 1% Cream, once daily

  • DrugAzelaic acid 15% Gel

    Topical Gel applied twice daily

06

What researchers measure

Primary outcomes

  1. Success Rate

    Percentage of subjects who achieve "Clear" (Score 0) or "Almost Clear" (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score. Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale: Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)

    Time frame: Week 12

  2. Absolute Change in Inflammatory Lesion Count

    Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)

    Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).

    Time frame: Baseline to Week 12

07

Results

Posted Jan 16, 2015

Participant flow

Part A Vehicle Control (12 Weeks)
Participant flow — Part A Vehicle Control (12 Weeks)
MilestoneCD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% Gel
Started451232
Completed414210
Not completed3722
Withdrew: Pregnancy20
Withdrew: Lack of efficacy01
Withdrew: Adverse event74
Withdrew: Withdrawal by subject187
Withdrew: Protocol violation21
Withdrew: Lost to follow-up78
Withdrew: Other (noted on crf)11
Part B Long Term Active Control 40 Weeks
Participant flow — Part B Long Term Active Control 40 Weeks
MilestoneCD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% Gel
Started412210
Completed351175
Not completed6135
Withdrew: Pregnancy51
Withdrew: Lack of efficacy23
Withdrew: Adverse event54
Withdrew: Withdrawal by subject2716
Withdrew: Protocol violation10
Withdrew: Lost to follow-up1610
Withdrew: Other (noted on ecrf)51
Part C Safety Follow up (4 Weeks)
Participant flow — Part C Safety Follow up (4 Weeks)
MilestoneCD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% Gel
Started350175
Completed350174
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimarySuccess Rate

Percentage of subjects who achieve "Clear" (Score 0) or "Almost Clear" (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score. Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale: Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Success Rate
Percentage of participantsCD5024 1% CreamCD5024 Vehicle Cream
Success Rate38.411.6
Statistical analysis
  • CD5024 1% Cream vs CD5024 Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.001
PrimaryAbsolute Change in Inflammatory Lesion Count

Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).

Time frame:
Baseline to Week 12
Reported as:
Mean · Lesion count change
Absolute Change in Inflammatory Lesion Count
Lesion count changeCD5024 1% CreamCD5024 Vehicle Cream
Absolute Change in Inflammatory Lesion Count-20.5 ± 15.95-12.0 ± 13.55
Statistical analysis
  • CD5024 1% Cream vs CD5024 Vehicle Cream · ANCOVA · p = <0.001 · Mean difference (net): -8.13 · 95% CI -10.12 to -6.13
SecondaryPercent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)

Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).

Time frame:
Baseline to Week 12
Reported as:
Mean · Percentage of change in lesion counts
Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)
Percentage of change in lesion countsCD5024 1% CreamCD5024 Vehicle Cream
Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)-64.9 ± 39.91-41.6 ± 38.83
Statistical analysis
  • CD5024 1% Cream vs CD5024 Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.001

Adverse events

Collected over Time of signed informed consent to study end (~ 58 wks). Treatment emergent adverse events - occurred on date of 1st use of medication or after, except those reported from Day 1 lab data as blood sample was to be drawn before the time of 1st dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD5024 1% Cream - Part A—3/452 (0.7%)30/452 (6.6%)
CD5024 Vehicle Cream - Part A—1/231 (0.4%)10/231 (4.3%)
CD5024 1% Cream - Part B—7/412 (1.7%)93/412 (22.6%)
Azelaic Acid 15% Gel - Part B—8/210 (3.8%)47/210 (22.4%)
CD5024 1% Cream - Part C—0/350 (0%)4/350 (1.1%)
CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Part C—1/175 (0.6%)0/175 (0%)
CD5024 1% Cream - Overall—10/452 (2.2%)110/452 (24.3%)
CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Overall—9/232 (3.9%)52/232 (22.4%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventCD5024 1% Cream - Part ACD5024 Vehicle Cream - Part ACD5024 1% Cream - Part BAzelaic Acid 15% Gel - Part BCD5024 1% Cream - Part CCD5024 Vehicle Cream/Azelaic Acid 15% Gel - Part CCD5024 1% Cream - OverallCD5024 Vehicle Cream/Azelaic Acid 15% Gel - Overall
Atrial fibrillationCardiac disorders0/4520/2310/4122/2100/3500/1750/4522/232
Transient ischaemic attackNervous system disorders0/4520/2311/4122/2100/3500/1751/4522/232
Renal failure acuteRenal and urinary disorders0/4520/2310/4122/2100/3500/1750/4522/232
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4520/2310/4120/2100/3501/1750/4521/232
AscitesGastrointestinal disorders0/4520/2310/4120/2100/3501/1750/4521/232
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4520/2310/4121/2100/3500/1750/4521/232
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4520/2310/4121/2100/3500/1750/4521/232
Acute myocardial infarctionCardiac disorders0/4520/2311/4121/2100/3500/1751/4521/232
Lobar pneumoniaInfections and infestations0/4520/2310/4121/2100/3500/1750/4521/232
ShockVascular disorders0/4520/2310/4121/2100/3500/1750/4521/232
Most frequent other events
Most frequent other events
EventCD5024 1% Cream - Part ACD5024 Vehicle Cream - Part ACD5024 1% Cream - Part BAzelaic Acid 15% Gel - Part BCD5024 1% Cream - Part CCD5024 Vehicle Cream/Azelaic Acid 15% Gel - Part CCD5024 1% Cream - OverallCD5024 Vehicle Cream/Azelaic Acid 15% Gel - Overall
NasopharyngitisInfections and infestations12/4526/23154/41231/2101/3500/17563/45234/232
Upper respiratory tract infectionInfections and infestations6/4522/23131/41214/2102/3500/17537/45216/232
HeadacheNervous system disorders13/4524/23117/4128/2101/3500/17526/45210/232

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(Years)CD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% GelTotal
Mean49.9 ± 12.1551.6 ± 11.9250.4 ± 12.09
Sex: Female, Male
Sex: Female, Male(Participants)CD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% GelTotal
Female314152466
Male13780217
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% GelTotal
Hispanic or Latino552378
Not Hispanic or Latino396209605
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% GelTotal
American Indian or Alaska Native000
Asian336
Native Hawaiian or Other Pacific Islander000
Black or African American639
White437220657
More than one race000
Unknown or Not Reported5611
Skin Photo Type
Skin Photo Type(Participants)CD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% GelTotal
I391655
II18590275
III16786253
IV512677
V81119
VI134
08

Study locations

50 sites
  • UAB Dermatology Clinical Research
    Birmingham, Alabama 35233, United States
  • Northwest AR Clinical Trials Center
    Rogers, Arkansas 72758, United States
  • Dermatology Research Associates
    Los Angeles, California 30127, United States
  • University Clinical Trials
    San Diego, California 92123, United States
  • Research Across America
    Santa Ana, California 92705, United States
  • Cherry Creek Research, Inc.
    Denver, Colorado 80209, United States
  • The Center for Clinical & Cosmetic Research
    Aventura, Florida 33180, United States
  • The Dermatology and Aesthetic Center
    Boca Raton, Florida 33486, United States
  • North Florida Dermatology Associates
    Jacksonville, Florida 32204, United States
  • FXM Research Miramar
    Miramar, Florida 33027, United States
  • MedaPhase, Inc.
    Newnan, Georgia 30263, United States
  • Laser & Skin Surgery Center of Indiana
    Carmel, Indiana 46032, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • The South Bend Clinic, LLP
    South Bend, Indiana 46617, United States
  • Derm Research, PLLC
    Louisville, Kentucky 40217, United States
  • Lawrence Green, MD, LLC
    Rockville, Maryland 20850, United States
  • Henry Ford Health Systems Department of Dermatology
    Detroit, Michigan 48202, United States
  • Grekin Skin Institute
    Warren, Michigan 48088, United States
  • Central Dermatology PC
    Saint Louis, Missouri 63117, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • Anderson & Collins Clinical Research,
    Edison, New Jersey 08817, United States
  • PMG Research of Charlotte
    Charlotte, North Carolina 28277, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Department of Dermatology - Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Dermatology Research Center of Cincinnati
    Cincinnati, Ohio 45220, United States
  • Haber Dermatology Clinical Research Center
    South Euclid, Ohio 44118, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • Baker Allergy, Asthma and Dermatology Research Center
    Lake Oswego, Oregon 97035, United States
  • PMG Research of Charleston
    Mount Pleasant, South Carolina 29464, United States
  • Palmetto Clinical Trial Services, LLC
    Simpsonville, South Carolina 29681, United States
  • TriCities Skin and Cancer
    Johnson City, Tennessee 37604, United States
  • Dermatology Associates of Kingsport, PC
    Kingsport, Tennessee 37660, United States
  • DermResearch, Inc.
    Austin, Texas 78759, United States
  • Modern Research Associates
    Dallas, Texas 75231, United States
  • Center for Clinical Studies
    Houston, Texas 77030, United States
  • Progressive Clinical Research
    San Antonio, Texas 78229, United States
  • Dermatology Research Center, Inc.
    Salt Lake City, Utah 84117, United States
  • The Education & Research Foundation, Inc.
    Lynchburg, Virginia 24501, United States
  • PLLC dba Dermatology Associates
    Seattle, Washington 98101, United States
  • The Polyclinic
    Seattle, Washington 98122, United States
  • Stratica Medical Inc
    Edmonton, Alberta T5K 1X3, Canada
  • Derm Research@888 Inc.
    Vancouver, British Columbia V5Z 3Y1, Canada
  • Dermadvances Research
    Winnepeg, Manitoba R3C 1R4, Canada
  • Nexus Clinical Research
    St John's, Newfoundland and Labrador A1A 5E8, Canada
  • Eastern Canada Cutaneous Research Associates
    Halifax, Nova Scotia B3H 1Z4, Canada
  • Skin Centre for Dermatology
    Peterborough, Ontario K9J 1Z2, Canada
  • Toronto Research Centre, Inc.
    Toronto, Ontario M3H 5Y8, Canada
  • Windsor Clinical Research, Inc.
    Windsor, Ontario N8W 5L7, Canada
  • Innovaderm Research. Inc
    Montreal, Quebec H2K 4L5, Canada
  • Siena Medical
    Montreal, Quebec H3Z 2S6, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Jul 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 6 months after primary completion. A results delay was requested in Jan 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2011
First posted
Dec 16, 2011
Start
Dec 2011
Primary completionActual
Jul 2013
CompletionActual
Aug 2013
Results delay requested
Jan 27, 2014
Results first posted
Jan 16, 2015
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01493687
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Dec 16, 2011
Start date
Dec 2011
Primary completion
Jul 2013
Completion
Aug 2013
Results posted
Jan 16, 2015
Last update
Feb 18, 2021

Study contacts

Michael Graeber, M.D.
study director · Galderma R&D, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion